Clinical Trial Update: A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports completion of a Phase 1 pivotal bioequivalence study of the liposomal doxorubicin formulation DOXIL/CAELYX in patients with a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• Doxil/Caelyx (liposomal doxorubicin)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Neoplasms, Neoplasms, Ovarian | Phase 1 | Status: COMPLETED